HAEMONETICS Business Summary

Haemonetics Corporation (HAE) operates a high-margin medical technology business model centered on a "razor-razorblade" strategy, generating revenue through the sale of automated blood and plasma processing hardware alongside a high volume of recurring, single-use disposables and specialized software like SafeTrace®. The company’s operations are divided into three primary segments: Plasma, which provides end-to-end collection solutions for the biopharmaceutical industry; Hospital, focusing on hemostasis management (TEG® 6s), cell salvage, and the high-growth Interventional Technologies suite; and Blood Center, which facilitates component collection for donor centers. Following the 2025 divestiture of its Whole Blood business and the January 2026 acquisition of Vivasure Medical, Haemonetics has pivoted toward the $1 billion vascular closure and surgical suite markets. The company competes directly with Terumo BCT, Fresenius Kabi, and Macopharma, maintaining a dominant market share in automated plasma collection while positioning itself as a specialized leader in surgical blood management relative to its more diversified peers. Founded in 1971 by Allen Latham Jr., the inventor of the Latham Bowl, Haemonetics is currently led by President and CEO Christopher Simon, a former Senior Partner at McKinsey & Company. The executive leadership team was significantly strengthened in 2025 with the appointments of EVP and COO Frank W. Chan, Ph.D., and EVP and CCO Roy Galvin, both of whom brought over 25 years of medical device pedigree from Medtronic and Covidien. Financial strategy is directed by EVP and CFO James C. D’Arecca, formerly of Bausch + Lomb, while Michelle L. Basil serves as EVP and General Counsel. The company is overseen by a Board of Directors chaired by Ellen M. Zane, former CEO of Tufts Medical Center, and includes Michael J. Coyle, a former Medtronic executive. This leadership core is supported by a stable institutional investor base, including Vanguard and BlackRock, as the firm executes its long-term strategy to expand its footprint in the interventional cardiology and vascular surgery sectors.